H1B Report
Side-by-side comparison

Vertex Pharmaceuticals Incorporated vs WIPRO LIMITED

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Vertex Pharmaceuticals Incorporated
MARank #FEIN 04-3039129
Entity B
WIPRO LIMITED
NJRank #6FEIN 98-0154401

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricVertex Pharmaceuticals IncorporatedWIPRO LIMITED
Total filings97672,392
Certified %91.39%91.61%
Denied %0.61%0.37%
Withdrawn %3.07%1.37%
Cert-withdrawn %4.92%6.64%
Rank#6
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateMANJ

Outcomes — Vertex Pharmaceuticals Incorporated

DOL case-status mix.

Outcome breakdown: Certified 91.4%, Cert-withdrawn 4.9%, Withdrawn 3.1%, Denied 0.6%
Outcome breakdown
OutcomeShare
Certified91.4%
Cert-withdrawn4.9%
Withdrawn3.1%
Denied0.6%
Certified91.4%
Cert-withdrawn4.9%
Withdrawn3.1%
Denied0.6%

Outcomes — WIPRO LIMITED

DOL case-status mix.

Outcome breakdown: Certified 91.6%, Cert-withdrawn 6.6%, Withdrawn 1.4%, Denied 0.4%
Outcome breakdown
OutcomeShare
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%
Certified91.6%
Cert-withdrawn6.6%
Withdrawn1.4%
Denied0.4%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Vertex Pharmaceuticals Incorporated
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201033
FY201126
FY201229
FY201331
FY201473
FY201529
FY201633
FY201759
FY201852
FY201954
FY20208
FY202120
FY202232
FY202339
FY2024150
FY2025191
FY2026117
WIPRO LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20103,039
FY20113,025
FY20127,031
FY20136,574
FY20148,104
FY201511,824
FY201610,254
FY20175,012
FY20186,067
FY20194,154
FY202094
FY2021128
FY202297
FY2023554
FY20242,296
FY20252,289
FY20261,850

Top 5 occupations — Vertex Pharmaceuticals Incorporated

Top 5 occupations — WIPRO LIMITED

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.